Pyros Pharmaceuticals’ Abstract Accepted for Poster Presentation at the American Epilepsy Society (AES) 2023 Annual Meeting

PARSIPPANY, N.J.--()--Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, today details an abstract accepted for poster presentation at the American Epilepsy Society (AES) 2023 Annual Meeting, December 1-5, 2023 in Orlando.

Details of the AES poster presentation:

Title: Evaluation of Product Preparation and Adherence Trends in the Infantile Epileptic Spasms Syndrome (IESS) Treated with Vigabatrin Powder Solution: FAERS Database
Poster Number: 2.500
Date and Time: Poster Session 2, Sunday, December 3, 2023
Location: Orange County Convention Center, West Concourse, West Hall C, Level 2

About Pyros

Pyros Pharmaceuticals is developing enhanced specialty pharmaceuticals for rare diseases. Pyros Pharmaceuticals’ goal is to elevate the standard of care for infantile spasms with treatment options that can make a significant difference for affected children. Our enhanced therapies and comprehensive support services will help providers and caregivers by easing navigation through the complexities of the patient journey.

For more information, please visit: www.pyrospharma.com

Forward-Looking Statements

The Company has made statements throughout this press release which constitute forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any results, levels of activity, performance or achievements expressed or implied by any such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “hopes,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “likely,” “potential,” or “continue” or the negative of these terms and similar words. Although management believe that the expectations reflected in these forward-looking statements are reasonable, management cannot guarantee future results, levels of activity, performance or achievements. Furthermore, management undertakes no obligation to update any forward-looking statements for any reason unless required to do so by law.

Contacts

Edwin Urrutia
Chief Operating Officer
edwin@pyrospharma.com
201-743-9468

Social Media Profiles

Contacts

Edwin Urrutia
Chief Operating Officer
edwin@pyrospharma.com
201-743-9468